The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/169851

Please be advised that this information was generated on 2018-01-13 and may be subject to change.
The early postnatal nutritional intake of preterm infants affected neurodevelopmental outcomes differently in boys and girls at 24 months

Viola Christmann (viola.christmann@radboudumc.nl)1, Nel Roeleveld2-3, Reina Visser4, Anjo J.W.M. Janssen5, Jolanda J.C.M. Reuser6, Johannes B. van Goudoever7,8, Arno F.J. van Heijst1
1.Department of Paediatrics, Subdivision of Neonatology, Radboudumc Amalia Children’s Hospital, Radboud university medical center, Nijmegen, The Netherlands
2.Department for Health Evidence, Radboud Institute for Health Science, Radboud university medical center, Nijmegen, The Netherlands
3.Department of Pediatrics, Radboudumc Amalia Children's Hospital, Radboud university medical center, Nijmegen, The Netherlands
4.Department of Paediatrics, Leiden University Medical Centre, Leiden, The Netherlands
5.Department of Rehabilitation, Paediatric Physical Therapy, Radboud university medical center, Nijmegen, The Netherlands
6.Department of Medical Psychology, Radboud university medical center, Nijmegen, The Netherlands
7.Department of Paediatrics, VU University Medical Center Amsterdam, Amsterdam, The Netherlands
8.Department of Paediatrics, Emma Children’s Hospital – AMC Amsterdam, Amsterdam, The Netherlands

ABSTRACT

Aim: This study assessed whether increased amino acid and energy intake in preterm infants during the first week of life was associated with improved neurodevelopment at the corrected age (CA) of 24 months.

Methods: We evaluated preterm infants from two consecutive cohorts in 2004 (Cohort 1) and 2005 (Cohort 2) with different nutritional intakes in the Netherlands. Nutritional intake and growth were recorded until week 5 and after discharge. Neurodevelopment was determined using the Bayley Scales of Infant Development – Second Edition at a CA of 24 months.

Results: Compared to Cohort 1 (n = 56), Cohort 2 (n = 56) received higher nutritional intake during week 1 (p < 0.001). The weight gain in Cohort 2 was higher until week 5, especially among boys (p < 0.002). The mean Mental Developmental Index (MDI) scores did not differ, but Cohort 2 was associated with an increased chance of having an MDI ≥ 85, with an odds ratio of 6.4 and 95% confidence interval (CI) of 1.5–27.4, among all girls with a higher protein intake (5.3, 1.2–23.3). The Psychomotor Developmental Index increased with increasing nutritional intake, especially among boys (β-coefficient 3.1, 95% CI 0.2–6.0).

Conclusion: Higher nutritional intake was associated with different improvements in growth and neurodevelopment in boys and girls.

INTRODUCTION

In addition to promoting growth similar to intra-uterine foetal growth, adequate functional development is the main goal of nutritional supplementation for preterm infants (1). Postnatal growth has been associated with neurodevelopmental outcomes in very low birthweight (VLBW) infants (2,3). In addition to postnatal weight gain, head growth may serve as a predictor of brain growth and therefore of neurodevelopmental outcomes (4). Follow-up studies of children born preterm have indicated that subnormal head growth predicted poorer intelligence quotient scores at three and eight years of age (5,6). Poindexter et al. (7) associated low early amino acid intake with increased risks

Key notes
- This study assessed whether increased amino acid and energy intake in preterm infants during the first week of life was associated with improved neurodevelopment at the corrected age of 24 months.
- We evaluated preterm infants from two consecutive cohorts with different nutritional intakes in the Netherlands – 56 in 2004 and 56 in 2005.
- Higher nutritional intake was associated with different improvements in growth and neurodevelopment in boys and girls.
of having a small-for-age head circumference (HC) at 18 months of age, specifically in boys.

In a retrospective study, Stephens et al. (8) determined that higher nutritional intake in the first week of life was associated with higher Mental Developmental Index (MDI) scores and related this increase to higher protein and energy intakes. Van den Akker et al. (9) suggested that the effects of nutritional interventions in the first few days following birth may be gender specific. VLBW boys, but not girls, were affected by low amino acid and energy intakes when assessed at a corrected age (CA) of 24 months. Previously, we demonstrated that increased amino acid and energy intakes during the first week of life were associated with a statistically significant short-term improvement in weight gain in VLBW infants (10). A secondary analysis of these data revealed that this was mainly based on improvement in male infants.

In this study, we investigated the neurodevelopment of the surviving infants of the original cohorts in relation to early nutritional intake. We hypothesised that nutritional supplementation during the first week would not only improve weight gain in the early postnatal period, but would also lead to improved head growth and neurodevelopmental outcomes at a CA of 24 months, specifically in boys.

METHODS

This study evaluated the long-term outcome data of a previously described prospective cohort study that was conducted during two consecutive years, 2004 (Cohort 1) and 2005 (Cohort 2), to evaluate a change in the composition of standard parenteral nutrition (PN) (10). The study was approved by the local ethics committee. The cohort characteristics, the nutritional protocol and its modification and the short-term results were described in detail in the previous paper (10). The original study included preterm infants born before 34 weeks of gestation who were admitted to our tertiary neonatal intensive care unit at the Radboud university medical center in the Netherlands on the first day of life on the assumption that PN would be needed for at least five days. Infants with major congenital malformations or asphyxia were excluded from the study. During both time periods, no major changes in clinical practice occurred and all infants received nutrition according to standard institutional protocols. The two cohorts primarily differed in PN intake which consisted of standard components, with higher amounts of amino acids and carbohydrates for Cohort 2. According to the new protocol, Cohort 2 achieved full PN two days earlier than Cohort 1, at postnatal day 4 versus 6, respectively (10).

The intake of all nutrients via both PN and enteral feeding, as well as growth characteristics, was recorded daily during the first two weeks, weekly until week 5 and at term-CA. Based on the information in the patient charts, the mean daily weight gain was calculated weekly for the first five weeks, according to Patel’s formula (11).

This study included the surviving participants of the original cohorts who received standard follow-up care provided for VLBW infants born prior to 32 weeks of gestation or with a birthweight of <1500 g. In accordance with the national follow-up programme, anthropometric data were recorded at the CAs of six months, 12 and 24 months. The head circumference standard deviation score (HC SDS) was calculated using the Swedish growth reference for preterm infants and the Dutch reference of the nationwide growth study from term-CA onwards (12,13). SDSs for weight and length were calculated using the Dutch reference (12). In addition, a neurodevelopmental assessment using the Bayley Scales of Infant Development – Second Edition (BSID-II) was performed at 24 months of CA, resulting in MDI and Psychomotor Developmental Index (PDI). Scores of 85 or above were categorised as normal outcomes, whereas scores between 70 and 85 reflected moderate impairment and scores below 70 indicated severe impairment. (14) We assumed the diagnosis of normal neurodevelopmental outcome as clinically relevant and therefore dichotomised the MDI and PDI scores with a cut-off score of ≥85 reflecting normal outcome and score of below 85 reflecting neurodevelopmental impairment.

The original cohort study was powered to assess differences in postnatal growth. As this study only evaluated the surviving infants of these cohorts, no power calculation was carried out. The statistical analyses were performed using IBM SPSS statistics, version 22.0 for Windows (IBM SPSS Inc., Chicago, IL, USA). As the values of the continuous variables were normally distributed, mean differences with 95% confidence intervals (95% CI) were calculated between the two cohorts. For dichotomous data, odds ratios (OR) with 95% CIs were calculated. Subsequently, linear regression analyses were performed to assess the effects on the continuous MDI and PDI scores of infants belonging to Cohort 1 or 2. These analyses were also used for protein and energy intake in week 1, separately and simultaneously, adjusted for a potential confounder set that included gender, gestational age (GA), birthweight, maternal education, infant respiratory distress syndrome (IRDS), days on ventilator, indomethacin treatment and late-onset sepsis. This confounder set was reduced if the model was unstable or when interpretation issues called for greater precision, by manually excluding those variables that did not change the effect estimate by more than 10% when they were excluded. Logistic regression analyses were performed for the dichotomous outcomes MDI ≥ 85 and PDI ≥ 85. All analyses were performed for the total study population and separately for the subgroups of boys and girls.

RESULTS

The original Cohort 1 comprised 68 infants (38 girls), while Cohort 2 comprised 79 infants (37 girls). The detailed cohort characteristics have previously been reported (10). For this study, we evaluated all 112 surviving children who visited the routine follow-up at the CA of 24 months. A further six infants had died, two from Cohort 1 and four from Cohort 2, while three and nine infants from the two respective cohorts were not invited, according to the
criteria of the follow-up programme, and 7 and 10 infants did not participate in the 24-month follow-up (Fig. 1).

**Cohort characteristics**
The cohort characteristics for the participating children, and the potential determinants of the outcomes, are presented in Table 1. Mean GA and birthweight did not differ between the two cohorts, but the duration of mechanical ventilation was 1.4 days shorter for infants in Cohort 2. Concerning nutritional intake, Cohort 2 received 3.3 (95% CI 2.0–4.6) g/kg/week more protein than Cohort 1 and had a 92 (54–131) kcal/kg/week higher energy intake during the first week. These differences were slightly smaller during the second week.

Only small differences were seen between the two cohorts with regard to gender, the numbers of infants with prematurity-related morbidities and maternal education. The only exception was patent ductus arteriosus (PDA), and its treatment, which occurred more frequently among infants in Cohort 1. Independent of cohort status, male infants seemed to have had an increased risk of IRDS and chronic lung disease (CLD) compared to female infants (OR 2.5, 95% CI 1.1–5.6 and 3.1, 1.0–9.6, respectively).

**Growth and neurodevelopmental outcomes**
The outcome parameters postnatal growth velocity, HC SDSs and BSID-II scores are presented in Table 2. The infants in Cohort 2 exhibited a higher mean daily weight gain from birth through to week 5 compared to Cohort 1, with a mean difference of 1.8 (95% CI 0.7–3.0) g/kg/day that was mainly due to a 3.1 (1.3–4.8) g/kg/day higher weight gain in male infants. The HC SDS in week one was lower in Cohort 2 than Cohort 1, but at the CA of six months, the HC SDS was normal compared to the Dutch population for both cohorts. This means that infants in Cohort 2 achieved a greater catch-up growth for

---

**Figure 1** Consort diagram. PN = parenteral nutrition; VLBWI = very low birthweight infants (GA < 32 weeks or birthweight < 1500 g; BSID-II = Bayley Scales of Infant Development – Second Edition; GA = gestational age.
HC (0.6 SDS; 0.2–0.9) compared to Cohort 1. At the CA of 24 months, the weight, length and HC were not different between the cohorts and within the normal range compared to the reference population.

In Cohort 1, 10 infants could not be tested for MDI adequately, because they were unable to complete the tests or were easily distracted. As their parents reported concerns regarding their behaviour, and they all had PDI scores of <70, these infants were categorised into the group with an MDI of <85. One infant refused to cooperate with MDI testing and was excluded from the analysis. The mean MDI and PDI scores were not different between the two cohorts, either in the total group or in the subgroups of boys and girls. However, the girls in both cohorts achieved higher scores than the boys, especially in Cohort 1 with a mean difference for MDI of 1.8 (95% CI 0.1–3.5). Furthermore, an MDI below 85 seemed to be associated with having had a PDA (OR 1.9, 95% CI 0.8–4.7), IRDS (2.2, 0.8–6.0) or CLD (3.3, 1.1–10.1) and with ≤10 years of maternal education (4.0, 1.3–13.8). For children with a PDI below 85, the same associations were seen but with slightly lower effect estimates: PDI < 85 PDA (OR 1.6, 95% CI 0.8–3.8), IRDS (2.2, 1.0–4.8), CLD (2.6, 0.8–8.8) and maternal education (2.5, 0.8–7.6). Compared to girls, boys seemed to have increased risks of having an MDI below 85 (OR 5.1, 95% CI 1.8–14.0) and a PDI below 85 (1.9, 0.9–4.0).

**Effect of early nutrition on neurodevelopmental scores and outcomes**

Table 3 presents the results of the linear regression analysis of the effects of early nutritional intake on the continuous neurodevelopmental outcome scores adjusted for confounders. Table 4 presents the results of the logistic regression analysis of the chance to achieve a normal neurodevelopmental outcome in relation to early nutritional intake adjusted for confounders. The different nutritional protocols in Cohorts 1 and Cohort 2 did not influence the mean MDI scores, either in the total study.

---

**Table 1** Cohort characteristics and potential determinants of the outcomes

<table>
<thead>
<tr>
<th>Patient characteristics</th>
<th>Cohort 1 (n = 56), mean (SD)</th>
<th>Cohort 2 (n = 56), mean (SD)</th>
<th>Mean difference (C2–C1)</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gestational age in weeks*</td>
<td>29.3 (2.2)</td>
<td>29.6 (1.8)</td>
<td>0.3</td>
<td>–0.4 to 1.1</td>
</tr>
<tr>
<td>Birthweight in grams*</td>
<td>1124 (290)</td>
<td>1153 (330)</td>
<td>29</td>
<td>–87 to 146</td>
</tr>
<tr>
<td>Head circumference of week 1 in cm</td>
<td>26.5 (2.2)</td>
<td>26.7 (1.8)</td>
<td>–0.3</td>
<td>–1.1 to 0.6</td>
</tr>
<tr>
<td>Days of mechanical ventilation*</td>
<td>3.8 (4.3)</td>
<td>2.4 (3.5)</td>
<td>–1.4</td>
<td>–2.9 to 0.1</td>
</tr>
</tbody>
</table>

**Nutritional intake**

| Protein week 1 (g/kg/week) | 14.7 (3.4)       | 18.0 (3.6)               | 3.3                    | 2.0 to 4.6  |
| Protein week 2 (g/kg/week) | 21.1 (5.0)       | 22.8 (4.8)               | 1.8                    | –0.1 to 3.6 |
| Energy week 1 (kcal/kg/week)| 513 (94)        | 605 (111)                | 92                     | 54 to 131   |
| Energy week 2 (kcal/kg/week)| 710 (173)       | 777 (165)                | 68                     | 5 to 131    |

**Cohort characteristics and potential determinants of the outcomes**

<table>
<thead>
<tr>
<th>Potential determinants of the outcomes</th>
<th>Cohort 1 (n = 56), number (%)</th>
<th>Cohort 2 (n = 56), number (%)</th>
<th>OR (C1 versus C2)</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender, female*</td>
<td>32 (57)</td>
<td>27 (48)</td>
<td>1.4</td>
<td>0.7 to 3.0</td>
</tr>
<tr>
<td>IUGR</td>
<td>9 (16)</td>
<td>11 (20)</td>
<td>0.8</td>
<td>0.3 to 2.1</td>
</tr>
<tr>
<td>IRDS*</td>
<td>38 (68)</td>
<td>33 (59)</td>
<td>1.5</td>
<td>0.7 to 3.2</td>
</tr>
<tr>
<td>CLD</td>
<td>10 (18)</td>
<td>6 (11)</td>
<td>1.8</td>
<td>0.6 to 5.4</td>
</tr>
<tr>
<td>PDA</td>
<td>28 (50)</td>
<td>17 (30)</td>
<td>2.3</td>
<td>1.1 to 5.0</td>
</tr>
<tr>
<td>PDA treatment*</td>
<td>25 (45)</td>
<td>12 (21)</td>
<td>3.0</td>
<td>1.3 to 6.8</td>
</tr>
<tr>
<td>LOS*</td>
<td>26 (46)</td>
<td>26 (46)</td>
<td>1.0</td>
<td>0.5 to 2.1</td>
</tr>
<tr>
<td>NEC &gt; 1b</td>
<td>3 (5)</td>
<td>5 (9)</td>
<td>0.6</td>
<td>0.1 to 2.5</td>
</tr>
<tr>
<td>IVH grade 3/4</td>
<td>3 (5)</td>
<td>1 (2)</td>
<td>3.1</td>
<td>0.3 to 30.9</td>
</tr>
<tr>
<td>Maternal education* low/high (missing)</td>
<td>10/37 (9)</td>
<td>8/37 (11)</td>
<td>1.3</td>
<td>0.4 to 3.5</td>
</tr>
</tbody>
</table>

C1 = Cohort 1; C2 = Cohort 2; OR = Odds ratio; 95% CI = 95% Confidence interval; IUGR = Intra-uterine growth retardation defined as a birthweight < 10th percentile; IRDS = Infant respiratory distress syndrome; CLD = Chronic lung disease defined as supplemental oxygen for >28 days; PDA = Patent ductus arteriosus diagnosed by echocardiography; PDA treatment = Including up to three courses of indomethacin and, or, surgical ligation; LOS = Late-onset sepsis defined by positive blood culture and clinical signs of infection occurring more than 72 hours after birth; NEC = Necrotising enterocolitis defined by Bell’s stage > 1b; IVH = Intraventricular haemorrhage; Low maternal education = ≤10 years of education.

*Included in potential confounder set in multivariable analyses (IUGR, CLD and PDA not included because of large overlap with other variables and NEC and IVH not included because of small numbers).
population or in the subgroups of boys and girls. However, a 1 g/kg higher intake of protein adjusted for energy in week one was associated with an increase in the PDI score of 2.4 (95% CI 0.6–4.3), especially among the boys (3.1, 0.2–6.0). This led to an approximately 1.5 higher chance of having a PDI ≥ 85 per g/kg higher protein intake (OR 1.4, 95% CI 1.1–1.8), and this was also more pronounced among the boys (Table 4). Cohort 2 was associated with a markedly higher chance of having an MDI ≥ 85 in the total study population (6.4; 1.5–27.4), as well as for boys and girls separately. Among girls, a positive influence of protein intake on the chance of having an MDI ≥ 85, with or without an adjustment for energy intake, was also observed (5.3, 1.2–25.3 and 2.8, 1.1–6.8, respectively).

**DISCUSSION**

Our evaluation of two cohorts at the CA of 24 months indicated that infants who received more protein and energy during the first week of life demonstrated a short-term improvement in postnatal weight gain, especially among male infants, while catch-up growth in HC seemed to be improved as well. The mean BSID-II scores were not different between the two cohorts, and the MDI scores did not seem to be influenced by the nutritional protocol. However, we found differences in the subgroups of children, namely boys and girls. Children in Cohort 2 were more likely to have an MDI ≥ 85, which was clearly associated with a higher protein intake among girls, while higher protein intake had a positive effect on the PDI score among boys.

While HC growth has been related to neurodevelopmental outcome, two randomised trials demonstrated that impaired head growth was associated with the persistence of cumulative protein and energy deficits and that postnatal abnormal head growth was ameliorated via the optimisation of nutritional intake, especially parenteral intake (15,16). The improved catch-up in HC we saw with improved nutrition was in accordance with the results of the above-mentioned trials.

A systematic review evaluated the effects of increased nutritional intake in the neonatal period on
neurodevelopmental outcomes in VLBW infants, and the results were comparable to our cohorts (17). This review evaluated 15 studies with regard to differences in neurodevelopmental scores and survival without impairment. The relationship between increased nutrition and neurodevelopmental outcomes remained unclear, probably due to the variety of nutritional interventions and neurodevelopmental outcome measures. In contrast, we not only compared the differences between the cohorts, but also evaluated the mental developmental and psychomotor indices in relation to the individual nutritional intake of the first week, adjusting for a number of confounders of neurodevelopment and evaluated subgroups of children. In general, preterm infants have been shown to be at risk for adverse neurodevelopmental outcomes associated with socioeconomic status and gender, as well as with a number of clinical factors that may be related to each other (18). Therefore, it is difficult to evaluate the effect of a single determinant, such as nutritional intake. In our study, for instance, the diagnosis and treatment of PDA seemed to be important risk factors for adverse outcome, but children with a PDA also had a lower protein and energy intake during the first 2 weeks compared to children without PDA. However, by including treatment for PDA in our confounder set, we were able to estimate the effects of protein and energy intake independent of PDA and other determinants of neurodevelopmental outcomes in preterm-born children. The same holds true for the other relevant confounders included in our analyses. However, some residual confounding by maternal education may still have been present in our results due to the relatively large number of missing values for this variable.

There is no consensus on whether improvements in postnatal weight gain and neurodevelopment are a result of a higher intake of amino acids (2,3,19). A Cochrane review found no evidence that high doses of amino acids had a positive effect on neurological outcomes (20). In contrast, van den Akker et al. (9) presented the long-term outcome results of a randomised trial that evaluated the early administration of amino acids and indicated that the intervention group, especially the male infants who received amino acids immediately after birth, experienced fewer disabilities at the CA of 24 months. Vlaardingerbroek et al. (21) demonstrated that high levels of amino acids and nonprotein energy sources were needed to achieve an anabolic state in VLBW infants. Our findings are in accordance with the latter study because Cohort 2 received not only more amino acids, but also an increase in energy (9).

Gender seemed to be an important factor that determined the consequences of nutritional interventions, both in our study on short-term growth effects, and in other studies (9,10,22–24). While the general male disadvantage regarding mortality, morbidity and neurodevelopmental outcomes among VLBW infants is well established, the above-mentioned nutritional intervention studies found

| Table 3 Effects of early nutritional intake on neurodevelopmental outcome scores |
|---------------------------------|-----------------|-----------------|-----------------|
|                                | MDI score*      | PDI score*      |                 |
|                                | Crude / | Adjusted / | 95% CI | Crude / | Adjusted / | 95% CI |
| Total population (n = 112)     |          |              |        |          |              |        |
| Cohort 2                        | 1.12     | 2.56         | –2.58 to 7.70 | 3.07     | 1.78        | –4.52 to 8.09 |
| Protein week 1 and Energy week 1| –0.17 and | 0.37 and     | –1.33 to 2.08 and | 2.46 and | **2.44** and | **0.55 to 4.32** and |
| Energy week 1                   | 0.01     | –0.01        | –0.06 to 0.05 | –0.05    | –0.06       | –0.12 to 0.00 |
| Protein week 1                  | 0.12     | 0.18         | –0.68 to 1.04 | 1.16     | 0.80        | –0.22 to 1.83 |
| Energy week 1                   | 0.01     | 0.00         | –0.03 to 0.03 | 0.03     | 0.01        | –0.03 to 0.04 |
| Boys (n = 53)                   |          |              |        |          |              |        |
| Cohort 2                        | 5.98     | 6.79         | –2.71 to 16.28 | 5.69     | 2.47        | –7.68 to 12.61 |
| Protein week 1 and Energy week 1| 0.21 and | 0.52 and     | –2.41 to 3.44 and | 2.98 and | **3.08** and | **0.19 to 5.98** and |
| Energy week 1                   | 0.03     | 0.01         | –0.10 to 0.11 | –0.05    | –0.04       | –0.15 to 0.06 |
| Protein week 1                  | 0.88     | 0.64         | –0.89 to 2.18 | 1.74     | 1.26        | –0.44 to 2.97 |
| Energy week 1                   | 0.03     | 0.02         | –0.34 to 0.08 | 0.05     | 0.02        | –0.04 to 0.08 |
| Girls (n = 59)                  |          |              |        |          |              |        |
| Cohort 2                        | –0.41    | –0.57        | –6.87 to 5.72 | 1.70     | –0.97       | –10.21 to 8.28 |
| Protein week 1 and Energy week 1| –0.41 and | 0.06 and     | –2.14 to 2.26 and | 2.03 and | 1.38 and     | –1.67 to 4.42 and |
| Energy week 1                   | –0.00    | –0.05        | –0.08 to 0.05 | –0.05    | –0.04       | –0.13 to 0.05 |
| Protein week 1                  | –0.44    | –0.38        | –1.43 to 0.68 | 0.72     | 0.09        | –1.38 to 1.56 |
| Energy week 1                   | –0.01    | –0.01        | –0.04 to 0.02 | 0.01     | –0.01       | –0.05 to 0.04 |

MDI = Mental Developmental Index; PDI = Psychomotor Developmental Index; 95% CI = 95% Confidence interval.

Bold numbers = indicative of an effect. Linear regression effect sizes were estimated for four separate situations: (i) being a member of Cohort 2, (ii) the combination of protein and energy intake in week 1, (iii) protein intake in week 1 alone and (iv) energy intake in week 1 alone.

*All analyses were adjusted for the potential confounder set: gender, gestational age, birthweight, maternal education, infant respiratory distress syndrome, days on ventilator, indomethacin treatment and late-onset sepsis, unless otherwise indicated.

1Adjusted for gender, maternal education and days on ventilator only.

2Adjusted for maternal education only.
that higher intake was specifically advantageous for male infants (25,26). Male vulnerability in outcomes has been related to higher perinatal testosterone and cortisol concentrations and an impaired adaptive response to stress that may have an influence on brain development (27,28). Also, studies have demonstrated gender-specific differences in early brain maturation (29,30). All of this may indicate different requirements of nutritional intake for male and female infants in the early postnatal period, and this could explain the different effects on neurodevelopmental outcomes for boys and girls that we observed.

In accordance with the study of van den Akker et al. (9), our results indicate that both male and female infants were vulnerable to nutritional deficits, but may have had different needs. Even short-term interventions may have significant effects for male and female infants, either inducing harm if the nutritional intake is inadequate or preventing poor neurological outcomes if the nutritional needs are met.

In addition to the strengths mentioned above, this study also had some limitations. First, the patients were not randomly assigned to a treatment, but were recruited over two time periods. However, all patients received nutrition according to a standardised protocol, the data were recorded in the same standardised manner, and the results were corrected for disparities in patient characteristics and morbidities. Second, although we improved the nutritional intake in Cohort 2, these infants did still not receive the intake recommended by guidelines issued after the two study periods (1,10). This factor may have attenuated our results, for both boys and girls. Furthermore, this study was not designed and powered to evaluate gender differences. Nevertheless, our data are consistent with recent studies and thus indicate that it may be necessary to develop different nutritional strategies for specific subgroups of preterm infants.

**CONCLUSION**

This study showed that an increase in the intake of amino acids and energy during the first week of life was associated with improved short-term weight gain, possibly improved catch-up of head growth and several specific long-term neurodevelopmental outcomes among preterm-born boys and girls at the CA of two years. Our findings indicate a need for adequately powered and randomised studies to evaluate gender-specific nutritional needs in preterm infants.

**CONFLICT OF INTEREST**

Authors declare no financial activities relevant to this study; JBvG declares financial activities outside the submitted
work. He received honoraria from HiPP GmbH & Co and is currently receiving grants from Danone and Mead Johnson Nutrition. He has also received payments for lectures, including service on a speaker’s bureau, the Nestle Nutrition Institute, Baxter, Danone and Nutricia Nederland NV. Finally, he has received royalties from Reed Elsevier.

FUNDING
No funding.

References


